It has been claimed that the National Institute of Mental Health (NIMH) budget, which traditionally has been evenly balanced between basic and clinical research, has shifted sharply and that 90% of NIMH resources are funding basic research. The authors used public data sources to assess this claim: the Research Condition and Disease Categorization Database, ClinicalTrials.gov, and the NIMH Strategic Plan for Research for 2020-2024. From 2016 to 2019, NIMH expenditures on bipolar disorder research decreased 25%, and those for schizophrenia research decreased 17.5%. From 2003 to 2019, NIMH support for treatment trials for schizophrenia, bipolar disorder, and major depressive disorder decreased 90%. NIMH's Strategic Plan for Research for 2020-2024 suggests that the shift toward basic research will continue. Because NIMH's primary purpose is to develop better treatments for current patients as well as future ones, the authors recommend that the ratio of basic to clinical research be readjusted to approximately 50:50.
Keywords: Bipolar Disorder; Clinical drug studies; Schizophrenia.